Genentech, Novartis get FDA nod for self-injectable Xolair Sanofi bags oral rival to Novartis' injectable blockbuster Cosentyx Nasus posts data on Narcan rival, teeing up FDA approval filing Nanoparticle combo boosts drug penetration into solid tumors Lyndra's ultralong-acting pill shows promise in schizophrenia phase 2, teeing up pivotal trial Featured Story | By Nick Paul Taylor The FDA has approved a self-injectable form of Genentech and Novartis’ Xolair. Introducing the new prefilled syringe product will free patients from the need to visit healthcare providers to get treated. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Sanofi has licensed an oral IL-17A inhibitor from C4X Discovery. The deal positions Sanofi to deliver an oral alternative to injectable anti-IL-17 antibodies such as Novartis' Cosentyx and Eli Lilly’s Taltz. read more By Nick Paul Taylor Nasus Pharma has presented data from a pivotal trial of its opioid overdose treatment. The naloxone powder-based nasal spray was absorbed into the blood faster than Narcan, leading Nasus to detail plans to seek FDA approval this year. read more By Nick Paul Taylor Combining chemotherapeutic agents with hypoxia-activated prodrugs may enhance drug penetration into solid tumors and wipe out cancer cells, according to a preclinical study published in the journal Science Advances. read more By Amirah Al Idrus In a phase 2 study, patients taking Lyndra Therapeutics’ once-weekly schizophrenia pill, LYN-005, quickly reached therapeutic levels of the drug, according to data presented virtually Sunday at the Congress of the Schizophrenia International Research Society. The study pitted Lyndra’s treatment, an ultralong-acting version of the antipsychotic risperidone, against immediate-release risperidone in 34 patients diagnosed with schizophrenia or schizoaffective disorder. read more Resources Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: PerkinElmer Informatics Discover the benefits of a cloud-native ELN that delivers better performance, security, connectivity, total cost of ownership PLUS sub-second search results through even the largest data volumes. Sponsored by: PulsePoint Access this guide for the latest insights into how marketers can use data, technology, and personalized messaging to build vaccine confidence and drive successful immunization efforts. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: BC Platforms Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored by: Catalent Discover the current state of patient-focused dose design through clinical evidence, real-world case studies and patient preference-driven drug design solutions that can help develop better treatments and successful real-world outcomes. Sponsored by: Catalent This eBook features insights from experts in the industry on patient-centric drug development challenges and strategies on advancing drug design and development effectively. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from a dedicated early-phase development site to a dedicated late-phase manufacturing site. BD&L Summit for Life Sciences March 9–10, 2021 | Virtual Event Neuroprotection: Opportunities in Retinal Neurodegenerative Diseases April 13, 2021 | 1:15p.m. ET / 10:15a.m. PT Learn core elements: pricing, competitive assessments and epidemiology April 28-29, 2021 | 9:00am-3:30pm PST
Medical Affairs Strategic Summit (MASS) Virtual May 5-7, 2021 | Virtual Event TMF Virtual Summit May 18-20, 2021 | Virtual Event | 